Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Shorted: Short Interest Up 86.7% in September

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 59,859 shares, a growth of 86.7% from the August 31st total of 32,056 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 159,917 shares, the days-to-cover ratio is currently 0.4 days.

Fresenius SE & Co. Stock Performance

Shares of OTCMKTS FSNUY traded up $0.11 during trading hours on Wednesday, hitting $12.73. 26,708 shares of the stock were exchanged, compared to its average volume of 145,257. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The company’s 50 day moving average is $13.18 and its 200 day moving average is $12.41. The firm has a market capitalization of $28.68 billion, a P/E ratio of 16.11 and a beta of 0.62. Fresenius SE & Co. has a one year low of $10.33 and a one year high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. On average, research analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on FSNUY. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.